🟢 Incyte is trading 4.6% up today after a strong Q2 earnings beat and raised guidance

Incyte is trading 4.6% up today at $125.32 after reporting a strong second-quarter earnings beat and raising its full-year guidance.

• The rally is primarily driven by a one-time Opzelura benefit tied to a favorable CMS settlement, which boosted Q2 revenue and EPS while improving long-term margin visibility.
• The company saw solid underlying growth in its key products, Opzelura and Jakafi, with additional support coming from broader strength in the biotech sector.